Series A co-led by Novartis Venture Fund and
Delos Capital, with participation from OrbiMed, Insight Partners,
J.P. Morgan Life Sciences Private Capital, CRISPR Therapeutics,
Innovation Endeavors, Invus, Arc Ventures, and Deep Insight
Company is developing a new class of genomic
medicines based on naturally occurring genetic elements that may be
delivered using mRNA and lipid nanoparticles to precisely and
durably insert entire genes into safe harbor sites in the human
genome
Company is focused on advancing medicines that
can be redosed and titrated with curative intent for patients
suffering from genetic diseases, cancer, and autoimmune
conditions
BOSTON, June 25,
2024 /PRNewswire/ -- Exsilio Therapeutics
("Exsilio"), a biotechnology company developing genomic medicines
for a broad range of diseases, announced today its emergence from
stealth with $82 million in Series A
financing. The funding was co-led by Novartis Venture Fund and
Delos Capital, with participation from OrbiMed, Insight Partners,
J.P. Morgan Life Sciences Private Capital, CRISPR Therapeutics,
Innovation Endeavors, Invus, Arc Ventures, and Deep Insight.
Exsilio was seed-funded by OrbiMed.
Exsilio will use proceeds from the financing to advance its
genomic medicines based on naturally occurring, programmable
genetic elements that can precisely insert new genes into a cell
through mRNA intermediates. Exsilio's interdisciplinary team has
built a platform that combines predictive in silico modeling and
wet lab-based experimentation to discover and engineer such
elements for integration of therapeutic genes into safe harbor
sites. Because Exsilio's medicines are encoded in mRNA, they can be
delivered using existing lipid nanoparticle (LNP) platforms that
are safe, efficient, scalable, and cost-effective, and can be
redosed and titrated with curative intent.
"mRNA-based medicines allow for a software-like approach to
creating new medicines," said Tal
Zaks, M.D., Ph.D., who serves as Exsilio's Chairman and
Interim Chief Executive Officer. "Exsilio's approach leverages the
advantages of mRNA and goes a step further by encoding genes that
integrate permanently, offering the possibility of curative rather
than transient effects. The ability to insert whole genes with a
repeatable and titratable approach should allow us to treat genetic
diseases irrespective of the patient's individual mutation. This
financing will help us advance our genomic medicines and select
promising lead candidates so that we can bring much-needed new
options to patients."
"We were captivated by Exsilio's genomic medicines approach
that stands to enable large-gene integration in a safe
and redosable manner," said Aaron
Nelson, Managing Director at Novartis Venture Fund
and Exsilio Board Member. "Through this significant investment,
Exsilio will be able to select and advance promising candidates
for difficult-to-treat diseases."
"We believe that the vision of safely and durably integrating
therapeutic genes into a patient's genome requires using RNA-based
payloads that can leverage clinically validated non-viral gene
delivery technologies," said Henry
Chen, Managing Partner of Delos Capital and Exsilio Board
Member. "Exsilio is bringing together a singular group of people to
help establish this new pillar of genomic medicine."
About Exsilio Therapeutics
Exsilio Therapeutics
is developing genomic medicines that can be delivered in
lipid nanoparticles to durably and safely treat a
broad range of diseases, including genetic diseases, cancer,
and autoimmune conditions. Exsilio's technology is
based on naturally occurring genetic elements that can precisely
insert new genes into a cell through RNA intermediate templates.
Exsilio uses predictive in silico modeling and wet
lab-based experimentation to engineer such elements for precise
insertion of therapeutic genes into safe harbor sites of
disease-relevant cells. Because Exsilio's medicines are encoded in
mRNA, they can be delivered using validated, non-viral delivery
platforms that are safe, efficient, scalable, and cost-effective,
and that allow redosing to effect with a curative intent. For more
information, follow us on LinkedIn.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/exsilio-therapeutics-launches-with-82-million-series-a-financing-to-develop-redosable-genomic-medicines-for-a-broad-range-of-diseases-302179289.html
SOURCE Exsilio